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TPNDesign: Prospective, open-label, multicenter, clinical trial on adult inpatients with type 2 diabetes on a
non-critical setting with indication for TPN. Patients were randomized on one of these two regimens:
100% of RI on TPN or 50% of Regular insulin added to TPN bag and 50% subcutaneous GI. Data were
analyzed according to intention-to-treat principle.
Results: 81 patients were on RI and 80 on GI. No differences were observed in neither average total daily
dose of insulin, programmed or correction, nor in capillary mean blood glucose during TPN infusion
(165.3 ± 35.4 in RI vs 172.5 ± 43.6 mg/dL in GI; p ¼ 0.25). Mean capillary glucose was significantly lower
in the GI group within two days after TPN interruption (160.3 ± 45.1 in RI vs 141.7 ± 43.8 mg/dL in GI;
p ¼ 0.024). The percentage of capillary glucose above 180 mg/dL was similar in both groups. The rate of
capillary glucose 70 mg/dL, the number of hypoglycemic episodes per 100 days of TPN, and the per-
centage of patients with non-severe hypoglycemia were significantly higher on GI group. No severe
hypoglycemia was detected. No differences were observed in length of stay, infectious complications, or
hospital mortality.
Conclusion: Effectiveness of both regimens was similar. GI group achieved better metabolic control after
TPN interruption but non-severe hypoglycemia rate was higher in the GI group.
Clinical trial registry: This trial is registered at clinicaltrials.gov as NCT02706119.
© 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diabetes mellitus has reached epidemic proportions in most
parts of theworld [1]. The estimated prevalence of diabetes in Spain
is of 14% of the adult population [2]. The prevalence of type 2
diabetes mellitus in the hospital setting is also elevated, and in this
case, it is associated with increases in mortality, hospital stay, and
costs [3].
Prevalence of diabetes in patients who start total parenteral
nutrition (TPN) to either treat or prevent malnutrition is also
elevated [4]. Besides, the use of TPN is itself a risk factor for the
onset or aggravation of hyperglycemia, regardless of a prior history
of diabetes [5]. Values above 180 mg/dL are associated with a
greater incidence of complications and death in hospitalized pa-
tients who receive parenteral nutrition [4,6]. Difficulty to reach an
adequate metabolic control is higher in patients with diabetes
mellitus who require parenteral nutrition when compared with
patients with prediabetes or stress-induced hyperglycemia, despite
receiving higher doses of insulin [7].
The best insulin regimen to use in these patients remains un-
known, and few studies have examined the effectiveness and se-
curity of the regimens, especially in non-critically ill patients with
type 2 diabetes [8e11].
The most prevailing regimen to control hyperglycemia is the
introduction of regular insulin added to TPN bags and using sub-
cutaneous Regular insulin as a correction [7,10,12]. This regimen has
the advantage that it can deliver the insulin intravenously at a
steady rate alongside carbohydrates, reducing the risk of hypogly-
cemia, and, in malnourished patients with lack of subcutaneous
tissue, it may prevent the need for frequent insulin injections.
However other regimens have been proposed, on small scale
studies, generally retrospective, including the subcutaneous
administration of a long acting insulin such as Glargine [11,13e17],
NPH [9], NPL [18], Degludec [19] or non-specified [20]. These new
regimens based on long-acting insulins might achieve similar
safety andmetabolic control [13,14] and, at least theoretically, could
reduce glycemic variability, which has been associated with an
increase in morbidity and mortality in patients on TPN [21], and
facilitate the transition to basal-bolus hospital regimens once TPN
is reduced or interrupted [22].
Nevertheless, only three randomized prospective studies have
been published, all of them unicenter, small scale, and short
studies; and none of those assessed blood glucose control after TPNinterruption [13e15]. So new randomized, prospective, and
multicenter studies that compare different insulin regimens in
non-critically ill patients with diabetes who receive TPN with a
higher number of patients and a longer monitoring period are
required.
Our hypothesis is that two different insulin regimens (50%
Glargine insulin as basal component þ 50% Regular insulin as
nutritional component versus 100% Regular insulin added to the
TPN bag both as basal and nutritional component) could be equally
effective and safe during TPN infusion.
The aim of the INSUPAR trial was to compare the effectiveness
(metabolic control) and safety of 2 insulin regimens: with or
without Glargine as basal insulin in non-critically ill patients with
type 2 diabetes who are receiving TPN.
2. Materials and methods
This prospective randomized open-label study was carried out
involving 26 centers in Spain (23 university hospitals and 3 non-
university hospitals). The study was approved by the Spanish
Agency for the Regulation of Drug and Healthcare Products
(EUDRACT 2015-003954-42), the Research Ethics Committee pro-
vincial of Malaga and of every hospital where the study took place,
and registered at clinicaltrials.gov (NCT02706119).
2.1. Patients
The study included adult (>18 years) hospitalized non-critically
ill (i.e., patients in noneintensive care unit setting) type 2 diabetes
patients who planned to start with TPN (considering it provides
more than 70% of the estimated total energy expenditure using
HarriseBenedict equation taking into account stress factor) for any
cause for at least 5 days between June 2016 and March 2018.
Patients were excluded following these criteria: they were in
intensive care units, were type 1 diabetes mellitus or post-total
pancreatectomy diabetes, <18 years of age, pregnant, renal failure
stage 3b o superior (glomerular filtration rate below 45mL/min), or
with intradialytic parenteral nutrition (Supplementary Table 1).
Patients were considered to have diabetes as assessed according
to the international criteria [23]. Blood glucose levels were ob-
tained from capillary and the same glucose meter was provided
(Freestyle Optium; Abbott Diabetes Care Inc, Witney, Oxon, United
Kingdom) to every center. Hypoglycemia was defined as blood
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glucose values <54 mg/dL. Severe hypoglycemia was defined as
being associated with severe cognitive impairment regardless of
blood glucose level [16,24].2.2. Randomization and course
Upon establishing the inclusion in the study and signing the
informed consent, data of the patients were introduced by each
investigator in an online case report form that allocated treatment
arms to each patient.
Baseline data were recorded: demographic variables, diagnosis
on admission, prior comorbidity (Charlson Comorbidity Index;
anthropometric data (weight, height, BMI)); year of diagnosis of
type 2 diabetes, and treatment modality, concomitant prescription
of hyperglycemic drugs (steroids, somatostatin, tacrolimus or
cyclosporine), and nutritional assessment by SGA.
The initial total insulin (between 0.2 and 0.5 UI/kg of actual body
with scales of 0.1 UI/kg) was estimated by the physician experience
basing on blood glucose prior to the initialization of TPN, age,
weight, previous treatment, glomerular filtration rate among
others.
Eligible participants were randomized 1:1 to receive one of
these two possible insulin regimens:
 Regular insulin group (RI): 100% of insulin requirements
administered as Regular insulin (Actrapid HM; Novo Nordisk A/
S, Bagsværd, Denmark) added to the bag of TPN as basal and
nutritional component.
 Glargine insulin group (GI): 50% of insulin requirements
administered as Regular insulin (Actrapid HM; Novo Nordisk A/
S, Bagsværd, Denmark) as nutritional component added to the
bag of TPN þ 50% of insulin administered as subcutaneous
Glargine insulin U100 as basal component (Lantus SoloStar;
Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Ger-




monitor capillary glucose on days 1 and 2 after TPN was stopped.
Blood tests were obtained on day 1, 5 and previous to the
interruption of TPN or on day 15 of the study to measure plasma
venous glucose. Glycated hemoglobin [25] was measured at day 1.
Adjustments in insulin dose were made according to a previ-
ously designed algorithm (Supplementary Fig. 1 & Supplementary
Table 2). In both groups, corrections were made subcutaneously
with Regular insulin when capillary glucose was above 140 mg/dL.
Two-thirds of the total amount of correction insulin was added
daily to the previous regimen: in the RI group 100% to the TPN bag
and in the GI group 50% to the TPN bag and 50% to the subcu-
taneous Glargine insulin. If capillary glucose was below 100 mg/dL
insulin was lowered according to the above-mentioned algorithm.2.3. TPN prescription
Total energy expenditure was estimated per HarriseBenedict
equation [26] multiplied by a factor ranging between 1.1 and 1.4
in relation to the metabolic stress of the disease. We used actual
weight or adjusted weight [27] if BMI was above 25 kg/m2.
The TPN formulae in all hospitals were provided as a total
nutrient admixture (‘3 in 1’) solution containing carbohydrates,
proteins, and lipids. All the TPN patients were seen daily by a
member of the hospital Nutrition Unit, who made adjustments inaccordance with international guidelines [28e31]. TPN was admin-
istered through a central venous line used only for this purpose.
2.4. Outcome measures
Primary endpoint: mean capillary glucose during TPN infusion
up to 15 days maximum.
Secondary endpoint:
1) Percentage of capillary glucose above 180 mg/dL.
2) Mean capillary glucose 48 h after TPN interruption.
3) Glycemic variability (standard deviation and variation coeffi-
cient of capillary glucose)
4) Rate of hypoglycemia, percentage of patients with hypoglycemia
and percentage of capillary glucose below or equal to 70 mg/dL.
5) Complications during hospitalization:
a) Non-catheter and catheter related bloodstream infections:
they were identified as an elevated white blood cell count in
addition to one or more of the following: positive blood
cultures, chest x-ray suggestive of pneumonia, positive urine
culture, postoperativewound infection and use of antibiotics.
b) Length of stay
c) In-hospital mortality2.5. Statistical analysis
Data analysis was performed using SPSS version 22.0 [32]. The
KolmogoroveSmirnov test was used to assess whether the vari-
ables were normally distributed or not. We carried out both
intention-to-treat and per-protocol analysis. The hypothesis
contrast between proportions was done using the c2 test with
Fisher's exact test, when necessary. Hypothesis contrast for
continuous variables between groups used the t test for variables
that followed a normal distribution, and a non-parametric test
(ManneWhitney orWilcoxon) for variables that did not conform to
normal. Variables tested repeatedly over time (mean capillary
glucose) were also analyzed using repeated measures multiple
analysis of variance according to time and group. For all calcula-
tions, statistical significance was set at p < 0.05 for two-tails.
2.6. Sample size
To calculate sample size, we used previous data [7] about non-
critically ill diabetic patients who achieved mean blood capillary
glucose during PN infusion of 179 ± 46 mg/dL. To detect differences
in mean metabolic control during PN infusion of 25 mg/dL between
both groups (two tails)with a confidence interval of 95% anda power
of 80%, a sample of at least 104 patients is required (52 per group).
3. Results
3.1. Sample
2286 patients with TPN were initially assessed and finally 163
patients with type 2 diabetes were selected to participate and
signed the informed consent but 2 of them did not start TPN
(Supplementary Fig. 2). 12 patients did not achieve the expected 5
days of TPN.
No differences were observed in any of the baseline features
comparing both groups (Table 1): age, gender, renal function,
Charlson index, age at diagnosis of diabetes, rate of patients with
insulin and other antidiabetic medications prior to admission
(Supplementary Table 3), reason for admission, anthropometric
parameters, HbA1c and PN formulae.
Table 1
Patient and TPN baseline characteristics.
Variablea RI (N ¼ 80) GI (N ¼ 81) P value
n 80 81 e
Men (%) 71.3 65.4 0.154
Caucasians (%) 100 100 e
Age (years) 71.2 ± 10.8 70.8 ± 9.0 0.127
Glomerular filtration rate (mL/
min)
99.2 ± 44.6 95.8 ± 31.3 0.580
Charlson index 7.0 ± 3.1 6.6 ± 2.8 0.457
Type 2 diabetes mellitus
Duration (years) 10.1 ± 7.3 12.2 ± 8.5 0.152
Age of diagnosis (years) 61.1 ± 11.3 58.6 ± 11.1 0.158
Patients with insulin, n (%) 25 (32.1) 21 (25.9) 0.394
Insulin units (UI/kg/day) 0.33 ± 0.86 0.33 ± 0.92 0.930
Patients only with insulin, n (%) 4 (5.0) 7 (8.6) 0.360
Patients only with non-insulin
hypoglycemic treatments, n
(%)
48 (60.0) 52 (64.2) 0.583
Patients with any antidiabetic
drug, n (%)
74 (92.5) 74 (91.4) 0.790
Patients only with diet, n (%) 6 (7.5) 7 (8.6) 0.990
Reason for admission
Surgical, n (%) 44 (55.0) 40 (49.4) 0,745
Oncohematological 22 (27.5) 27 (33.8)
Medical 14 (17.5) 13 (16.3)
Anthropometric variables
Weight (kg) 73.2 ± 18.8 72.1 ± 14.1 0.570
Usual weight (kg) 79.2 ± 19.8 79.2 ± 16.7 0.445
Adjusted weight (kg) 64.7 ± 8.9 65.1 ± 8.9 0.075
Height (m) 1.63 ± 0.09 1.64 ± 0.09 0.368
BMI (kg/m2) 27.6 ± 6.5 26.8 ± 4.8 0.204
HarriseBenedict (kcal/day)b 1290.8 ± 170.2 1308.8 ± 175.0 0.656
Estimated total energy
expenditure (kcal/day)
1602.3 ± 218.4 1632.7 ± 242.0 0.375
Subjective global assessment
Well nourished, n (%) 30 (37.5) 22 (27.2) 0.193
Moderate malnutrition, n (%) 25 (31.3) 36 (44.4)
Severe malnutrition, n (%) 25 (31.3) 23 (28.4)
HbA1c
% 6.6 ± 1.0 6.6 ± 1.1 0.456
mmol/mol 49.5 ± 12.5 48.2 ± 11.4 0.494
TPN characteristics
Days with TPN (days) 9.7 ± 6.8 10.5 ± 7.4 0.883
Mean daily carbohydrates in PN
(g)
185.5 ± 31.1 188.3 ± 31.9 0.583
Mean daily amino acids in PN
(g)
80.7 ± 13.3 82.5 ± 14.6 0.652
Mean daily lipids in PN (g) 57.0 ± 11.4 56.2 ± 12.4 0.709
Mean daily carbohydrates in PN
(g/kgb)
2.82 ± 0.42 2.84 ± 0.44 0.554
Mean daily carbohydrates in
other fluids (g)
2.87 ± 6.9 4.26 ± 8.1 0,156
Mean daily amino acids in PN
(g/kgb)
1.23 ± 0.19 1.24 ± 0.18 0.482
Mean daily lipids in PN (g/kgb) 0.87 ± 0.18 0.85 ± 0.19 0.431
Mean daily kcal PN (kcal/day) 1638.3 ± 225.5 1647.8 ± 229.9 0.980
Total mean daily kcal PN þ in
other fluids (kcal/day)
1659.9 ± 237.2 1674.7 ± 243.9 0.872
Hyperglycemic drugs
Corticosteroids, n (%) 17 (21.3) 9 (11.1) 0.080
Tacrolimus, n (%) 0 (0.0) 1 (1.2) 0.319
Somatostatin, n (%) 7 (8.8) 5 (6.2) 0.534
Any drug that induces
hyperglycemiac, n (%)
22 (27.5) 15 (18.5) 0.176
a Values are mean ± SD unless otherwise stated.
b We used actual weight or adjusted weight if BMI was above 25 kg/m2.
c This includes the number of patients that were on any hyperglycemic drug; in
the RI group there were two patients with both Corticosteroids and Somatostatin.
G. Olveira et al. / Clinical Nutrition 39 (2020) 388e394 3913.2. Metabolic control
No statistically significant differences were observed comparing
mean values of different glycemic parameters (venous blood
glucose, capillary glucose, glycemic variability parameters, totalinsulin and capillary glucose decrements) neither during TPN
infusion nor on each day of the study (Supplementary Table 4).
Using repeated measures multiple analysis of variance, we found
significant differences in relation to time (a linear decrease) in both
groups. No differences were observed between groups neither in
mean capillary glucose nor in the descent of capillary glucose with
respect to the first day.
There were statistically significant differences in the rate of
capillary glucose70mg/dL, the number of hypoglycemic episodes
per 100 days of TPN and in the percentage of patients with non-
severe hypoglycemia (higher on GI) (Table 2). However, none of
the groups had any severe hypoglycemia episodes.
Two days after the interruption of TPN, we observed signifi-
cantly lower mean capillary glucose levels on GI group vs RI.
No other statistically significant differences were observed be-
tween the two groups regarding complications (Table 3).
When data were analyzed per-protocol (excluding 12 patients
that did not reach 5 days of TPN) the variables were still statistically
significant.4. Discussion
Our study is the first multicenter randomized clinical trial that
assesses the effectiveness and safety of two different modalities of
insulin therapy in non-critically ill diabetic patients who receive PN
with a long follow-up and a monitoring period following its
interruption.
Both regimens (50% Glargine insulin as basal component þ 50%
Regular insulin as nutritional component versus 100% Regular in-
sulin added to the TPN bag both as basal and nutritional compo-
nent) are equally effective to reach an adequate metabolic control
during PN infusion.
Clinical practice guidelines and consensus statements recom-
mend a target glucose range of 140e180 mg/dL for the majority of
non-critically ill patients, but more stringent goals may be appro-
priate for selected patients if this can be achieved without signifi-
cant low blood glucose events [8,33]. During PN mean total
capillary glucose, glycemic variability, and insulin dosewere similar
in both groups without finding significant differences in any day
(Supplementary Table 4). We did not find differences in the per-
centage of measurements above 180 mg/dL, values that have been
associated with an increase in morbidity and mortality [4,6,34], or
from 100 to 180 mg/dL. These results are in accordance to the
previously published randomized studies which compared subcu-
taneous Glargine versus Regular insulin added to PN in people with
diabetes [13,14,35].
As well as other authors [14], we have observed a tendency to
have higher capillary glucose in GI group during the first days of
TPN (the goal of reaching mean capillary glucose below 180 mg/dL
could only be reached after three days in GI. On the contrary, RI
achieved it on the first day). Nonetheless, we did not observe dif-
ferences in metabolic control at different moments of the day be-
tween groups. Metabolic control was significantly better in GI on
the 48 h after the interruption of PN; Glargine insulin pharmaco-
dynamics, with a duration of action close to 24 h, could explain this
difference.
Mean glycemic control reached with both regimens was similar
to the results published in other prospective studies in patients
with diabetes and PN (Supplementary Table 4) [13,14] or mildly
superior to the one achieved with insulin pumps [15]. Our results
are clearly better than the ones obtained in patients with hyper-
glycemia treated only with subcutaneous insulin regimens (basal
plus correction insulin regimen, with no insulin added to PN bag)
[17,20]. Despite this, one third of the patients showed a percentage
Table 2
Outcomes - metabolic control.
Variablea RI (n ¼ 80) GI (n ¼ 81) P value
Insulin
Mean total daily insulin (IU) 44.2 ± 25.3 48.9 ± 25.8 0.412
Mean correction daily insulin (IU) 9.9 ± 8.0 11.5 ± 7.8 0.113
Mean total daily insulin (IU/kg) 0.62 ± 0.32 0.69 ± 0.37 0.321
Mean correction daily insulin (IU/kg) 0.14 ± 0.12 0.16 ± 0.1 0.095
Mean total daily insulin/10 g of
carbohydrates in TPN (IU)
2.4 ± 1.1 2.6 ± 1.4 0.156
Mean capillary glucose
08:00 h (mg/dL) 163.4 ± 36.1 169.2 ± 45.0 0.374
13:00 h (mg/dL) 169.6 ± 37.1 178.5 ± 46.9 0.187
20:00 h (mg/dL) 167.6 ± 38.3 169.4 ± 45.5 0.795
00:00 h (mg/dL) 155.5 ± 38.4 167.9 ± 47.0 0.087
During TPN (mg/dL) 165.3 ± 35.4 172.5 ± 43.6 0.250
Mean post-TPN capillary blood glucose
48 h (mg/dL)
160.3 ± 45.1 141.7 ± 43.8 0.024
Mean Day 1 post-TPN capillary glucose
(mg/dL)
161.3 ± 47.7 143.1 ± 53.8 0.054
Mean Day 2 post-TPN capillary glucose
(mg/dL)
160.6 ± 47.3 143.3 ± 39.8 0.046
Hypoglycemic variables
Number of patients with capillary
glucose  70 mg/dL, n (%)
9 (11.2%) 22 (27.2%) 0.016
Number of patients with capillary
glucose < 54 mg/dL, n (%)
1 (1.2%) 7 (8.8%) 0.064
Number of severe hypoglycemia, n (%) 0 0
Number of hypoglycemia events/100
days of TPN
1.9 ± 6.1 4.9 ± 9.8 0.015
Capillary glucose %b
70 mg/dL (%) 0.8 ± 3.0 1.8 ± 3.5 0.011
71e100 mg/dL (%) 7.5 ± 10.4 7.0 ± 8.9 0.913
101e140 mg/dL (%) 29.2 ± 20.3 27.6 ± 23.3 0.430
141e180 mg/dL (%) 29.8 ± 16.1 26.4 ± 16.0 0.163
71e180 mg/dL (%) 66.7 ± 27.7 61.2 ± 30.0 0.227
>180 mg/dL (%) 32.7 ± 27.2 37.2 ± 30.5 0.435
Standard deviation of capillary glucose
(mg/dL)
40.4 ± 16.0 43.4 ± 19.0 0.292
Variation coefficient of capillary glucose
(%)
24.5 ± 8.1 25.5 ± 10.2 0.570
Bold signifies P-value below 0.05 (p < 0.05).
a Values are mean ± SD unless otherwise stated.
b Based on the total capillary glucose carried out during TPN infusion.
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by our group previously in people with diabetes [7].
The insulin regimen and monitoring system should also mini-
mize glycemic variability [36], as it has been associated with
increased hospital mortality during TPN but not in people with
diabetes [21]. Both variation coefficient and standard deviation of
capillary glucose were similar in both groups and with similar re-
sults to those published by other authors [14,15].
The number of hypoglycemic events was significantly higher in
GI, nevertheless, all of them were mild and none of them were
severe.
Insulin added to TPN bag has the advantage that it can deliver
the insulin intravenously at a steady rate alongside carbohydratesTable 3
Outcomes - complications.
Variablea RI (N ¼ 80) GI (N ¼ 81) P value
Length of stay (days) 31.1 ± 26.0 29.8 ± 22.0 0.870
Mortality (n, %) 11 (13.8) 13 (16.0) 0.682
Infectious complications
CLASBIb, n (%) 12 (15.0) 76 (5.0) 0.078
Sepsis, n (%) 7 (8.8) 3 (3.7) 0.210
Pneumonia, n (%) 3 (3.8) 3 (3.7) 1.000
Surgical site infection, n (%) 8 (10.0) 5 (6.3) 0.564
Urinary tract infection, n (%) 1 (1.3) 4 (4.9) 0.367
a Values are mean ± SD unless otherwise stated.
b Central line-associated bloodstream infections.reducing the risk of hypoglycemia [10]. In a previous study pub-
lished by our group in non-critically ill patients with PN [37] the
rate of low blood glucose events (<70 mg/dL) was clearly inferior
(only 0.8 per 100 days of PN and occurred in 6.8% of the patients) to
the one observed in our current study, especially in GI group
(Supplementary Table 4); however only 21.6% of the assessed cases
presented diabetes.
Hakeam et al. [14] were the only group describing a lower
percentage (although non-significant) of hypoglycemic events in
patients with diabetes and PN in Glargine group (5.7%) versus
Regular insulin added to PN (11.4%); lesser duration of the study
(only 6 days after randomization) might partially explain the dif-
ferences. Li et al. [15], comparing subcutaneous Glargine versus
subcutaneous continuous insulin infusions in patients with dia-
betes receiving PN, did not observe any severe hypoglycemia.
Oghazian et al., in stable critically ill patients with diabetes, did
observe a higher number of non-significant hypoglycemic events in
Glargine group during a period of 3 days [13]. Neff and Ramos et al.
[17,20] described low blood glucose events in patients with PN and
hyperglycemia treated only with subcutaneous insulin in 29% and
22% of the cases, respectively; sudden interruption of PN as well as
higher duration of PN [20] could be some of the factors that in-
crease the risk of hypoglycemia [37] in these patients. The per-
centage of hypoglycemia might reach up to 40% of the patients
with PN and hyperglycemia treated with infused intravenous
insulin [21].
We did not observe any differences in number of infectious
complications, length of stay or mortality (Table 3).
Similar to hyperglycemia, hypoglycemia is associated with
increased in-hospital mortality but the risk might be limited to
patients with spontaneous hypoglycemia and not to patients with
drug-associated hypoglycemia [38]. We did not observe differences
in mortality, length of stay or other complications between groups,
maybe because of the absence of severe hypoglycemia.
It is well established that an elevation in blood glucose is a risk
factor for infection [39]. Unlike other authors [13,14] that only
evaluated glycemic control, we have also assessed the incidence of
infectious and non-infectious complications but we did not find any
significant differences in any of these variables. Mortality was also
evaluated and it was similar in both groups, these figures are in
agreement with those previously published by us in subgroups of
people with diabetes [4].
Our study is, among the others of its kind, the one with the
largest number of patients recruited and the only one that is
multicenter. Besides, it includes a very homogeneous sample of
patients (all of them previously diagnosed with type 2 diabetes
mellitus, none with stress hyperglycemia and with very similar
composition of the TPN bags), it evaluates the use of insulin during
15 days of PN, it continues the follow-up 48 h after the interruption
of the PN, and it also includes the assessment of complications.
However, there are some limitations. First of all, the recruitment
was variable (from 1 to 15 patients) so the low recruitment of some
centers might have affected the analysis. There is also the fact that
we focus on non-critically ill patients with type 2 diabetes mellitus,
therefore we cannot apply these conclusions to another group of
patients; nevertheless we have chosen these patients because they
are the most difficult ones to control in previously published
studies [7]. Sample size was calculated to detect differences in
mean capillary glucose but not in complications so the conclusions
regarding complications should be taken cautiously. Besides,
although we have made an ample number of statistical compari-
sons, the parameters that reach significance (hypoglycemic events
and metabolic control after the interruption of PN) are concordant.
And finally, of the 161 patients who started TPN, 12 of them did not
reach 5 days of treatment, however, the results were still
G. Olveira et al. / Clinical Nutrition 39 (2020) 388e394 393statistically significant as both intention-to-treat and per-protocol
analysis.
In conclusion, we have observed that both regimens (50% sub-
cutaneous Glargine as basal component þ 50% Regular insulin as
nutritional component versus 100% Regular insulin added to total
parenteral nutrition bag (basal and nutritional component)) are
similar in relation to its effectiveness to achieve an adequate
metabolic control during PN infusion in non-critically ill patients
with diabetes so both regimens could be used. Nevertheless, GI
group achieved better metabolic control after TPN interruption and
non-severe hypoglycemia rate was higher in the GI group. These
data indicate that in patients with 100% Regular insulin added to
TPN bag, Glargine may improve the transition and control after its
interruption if it is prescribed previously [22].
This study opens the way for other clinical trials that might
evaluate other insulin regimens and in other group of patients with
hyperglycemia and PN.
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